Investment Rating - The report maintains the investment rating for the company [1] Core Views - The company is projected to experience significant revenue growth, with estimated revenues increasing from 891.76 million in 2024 to 1642.01 million by 2027, reflecting a compound annual growth rate (CAGR) of approximately 20.65% [5][7] - The net profit attributable to the parent company is expected to rise from 208.58 million in 2024 to 377.76 million in 2027, indicating a robust growth trajectory with a CAGR of about 28.05% [5][7] - The gross margin is anticipated to improve from 39.03% in 2024 to 44.98% in 2027, showcasing enhanced operational efficiency [5][7] Financial Summary - Revenue Forecast: - 2024: 891.76 million - 2025: 1118.01 million (growth rate: 25.37%) - 2026: 1361.01 million (growth rate: 21.74%) - 2027: 1642.01 million (growth rate: 20.65%) [5][7] - Net Profit Forecast: - 2024: 208.58 million - 2025: 241.55 million (growth rate: 15.81%) - 2026: 295.02 million (growth rate: 22.13%) - 2027: 377.76 million (growth rate: 28.05%) [5][7] - Key Financial Ratios: - PE ratio is projected to decrease from 45.73 in 2024 to 25.25 in 2027, indicating improved valuation metrics [5][7] - PB ratio is expected to decline from 4.92 in 2024 to 3.91 in 2027, reflecting a more attractive investment proposition [5][7] - Cash Flow: - Operating cash flow is forecasted to decrease from 263.31 million in 2024 to 226.69 million in 2025, before increasing to 424.05 million by 2027 [6][7]
603297:2024年年报及2025年一季报点评:显微镜业务复苏,25Q1业绩持续向好-20250428